Dade Responds to Ortho/MLA Joint Venture
In July 1994, J&J division Ortho Diagnostic Systems initiated a hematology joint venture with Medical Laboratory Automation to market MLA’s hemostasis instruments with Ortho’s hemostasis reagents, a big blow to Dade (then a subsidiary of Baxter), which for years had a similar arrangement with MLA. Now Dade has responded by signing a hematology partnership with Toa Medical Electronics.
You may also be interested in...
A year ago, Dade Behring, the nation's sixth largest diagnostics company, was facing a huge debt and very angry debt holders. Now, the company seems close to a deal that would allow it to cut the debt in half (to about $750 million) and give debtholders full ownership of Dade Behring. The company would file a voluntary pre-packaged bankruptcy in federal court, which would also enable it to start trading securities on the public equities market. Nothing is finalized, but sources say the company is confident it will prevail. Meanwhile, its financial performance is picking up, with strong growth in all core product lines.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.